• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Enasidenib mesylate

CAS No. 1650550-25-6

Enasidenib mesylate ( —— )

产品货号. M33941 CAS No. 1650550-25-6

Enasidenib mesylate 是一种有效的,可口服的,可逆的,选择性的 IDH2 突变酶抑制剂。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥511 有现货
10MG ¥748 有现货
25MG ¥1200 有现货
50MG ¥1795 有现货
100MG ¥2592 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥639 有现货

生物学信息

  • 产品名称
    Enasidenib mesylate
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Enasidenib mesylate 是一种有效的,可口服的,可逆的,选择性的 IDH2 突变酶抑制剂。
  • 产品描述
    Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
  • 体外实验
    Enasidenib (AG-221) reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Enasidenib induces differentiation and impairs self-renewal of IDH2-mutant leukemia cells, effects that are further enhanced by simultaneous inhibition of Flt3ITD. Enasidenib (AG-221) therapy induces differentiation of leukemic cells, with an increase in the CD11b+ population and a decrease in the c-Kit+ population in the peripheral blood at 2 wks.
  • 体内实验
    Treatment with enasidenib (AG-221) significantly improves survival in an IDH2-mutant acute myeloid leukemia (AML) primary xenograft mouse model. Enasidenib (AG-221), a mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Enasidenib treatment (10 mg/kg or 100 mg/kg bid) leads to a reduction in 2-HG in vivo (96.7% below pre-treatment levels). Moreover, Enasidenib treatment restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression (mean MEP% mean, 39% Veh vs 50% AG-221). Enasidenib therapy reverses the effects of mutant IDH2; a significant reduction is observed in DNA methylation, including 180 genes that have 20 or more hypomethylated differentially methylated cytosines (DMCs) following treatment. Enasidenib (100 mg/kg bid) treatment of mice engrafted with Mx1-Cre IDH2R140QFlt3ITD AML cells markedly reduces 2-hydroxyglutarate (2-HG) levels consistent with on target inhibition. Enasidenib inhibits mutant IDH2-mediated 2-HG production.
  • 同义词
    ——
  • 通路
    Metabolic Enzyme/Protease
  • 靶点
    Dehydrogenase
  • 受体
    Dehydrogenase
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    1650550-25-6
  • 分子量
    569.48
  • 分子式
    C20H21F6N7O4S
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO 中的溶解度 : ≥ 100 mg/mL (175.60 mM )
  • SMILES
    CS(O)(=O)=O.CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015
产品手册
关联产品
  • IDH889

    IDH889 是一种脑渗透剂、变构和突变特异性 IDH1 抑制剂。 IDH889 对 IDH1 R132* 突变具有有效的选择性(IDH1R132H、IDH1R132C 和 IDH1wt 的 IC50 值:0.02 μM、0.072 μM 和 1.38 μM)。

  • BI?3231

    BI 3231 是一种有效和选择性的羟基类固醇 17?-脱氢酶 13 HSD17B13 抑制剂,对 hHSD17B13 和 mHSD17B13 的 IC50 值分别为 1 和 13 nM。BI 3231 具有研究非酒精性脂肪性肝炎 (NASH) 和其他肝脏疾病的潜力。

  • TC HSD 21

    TC HSD 21 是一种有效的 17β 羟甾类脱氢酶 3 型 (17β-HSD3) 抑制剂,IC50 值为 14 nM,TC HSD 21 对 17β-HSD 同工酶和核受体具有良好的选择性。